Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03361956 · ClinicalTrials.gov registry record · Phase 2
An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection
A Phase 2 study, sponsored by Janssen Sciences Ireland UC.
- Completed
- Registry status
- Phase 2
- Development phase
- 232
- Enrollment target
NCT03361956 is a Phase 2 study that has completed, run by Janssen Sciences Ireland UC. The registered enrollment target is 232 participants.
The verdict
NCT03361956, a Phase 2 study, has completed, sponsored by Janssen Sciences Ireland UC.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 232 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate efficacy of 24 weeks of study treatment, in terms of changes in hepatitis B surface antigen (HBsAg) levels.
Interventions
- DRUG Placebo
- DRUG JNJ-56136379
- DRUG NA (ETV or TDF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2018-02-13 |
| Est. Completion | 2020-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03361956
The ClinicalTrials.gov registry entry for NCT03361956 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Sciences Ireland UC, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03361956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03361956 about?
NCT03361956 is a clinical study titled "An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection". The main purpose of this study is to evaluate efficacy of 24 weeks of study treatment, in terms of changes in hepatitis B surface antigen (HBsAg) levels.
What is the current status of trial NCT03361956?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 232 participants. The study started on 2018-02-13. Estimated completion is 2020-08-13.
What interventions are being tested in trial NCT03361956?
The interventions under investigation include: Placebo (DRUG), JNJ-56136379 (DRUG), NA (ETV or TDF) (DRUG).
Who is sponsoring clinical trial NCT03361956?
This trial is sponsored by Janssen Sciences Ireland UC, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.